Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

66.31 +0.16 (+0.23%)
Streaming Delayed Price Updated: 12:18 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
44 45 Next >
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Pummeled! These 5 Dividend Growth Stocks Are Down Big Time From Their 52 Week Highs
2022 has been nuts, right? After investing for more than a decade, I've never seen this kind of sustained daily volatility before. But, as always, I see short-term volatility as a long-term... 
Via Talk Markets
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Where Gilead Sciences Stands With Analysts
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: 
Via Benzinga
Gilead's Yescarta Scores FDA Approval As First CAR T-Cell Therapy For Earlier Lymphoma
Via Benzinga
High Dividend 50: Gilead Sciences
Gilead is offering an all-time high dividend yield of 5.0% and is trading at a forward price-to-earnings ratio of 9.1. Unfortunately, there are good reasons behind these seemingly attractive features... 
Via Talk Markets
At the Forefront of HIV Health and Healing in Spain: Ferran's Story
SOURCE: Gilead Sciences 
Via 3BL Media
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 13.94%. Currently, Gilead Sciences has a market... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc raised the price target on Block, Inc. (NYSE: SQ) from $175 to $180. Block shares rose 2.8% to $137.42 in pre-market trading. 
Via Benzinga
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
Hope for Haiti Kicks Off Fourth Annual Hike for Haiti Challenge Campaign to Provide Access to Education and Public Health
Feel-good global movement supported by high-profile ambassadors and brands helping to fund organization's $12M plan for school rebuilding and rehabilitation following the devastating 7.2 magnitude... 
Via Newswire.com
Advocating for Black Women With Triple-Negative Breast Cancer: Ricki's Story
SOURCE: Gilead Sciences 
Via 3BL Media
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Claflin University's Deeply Rooted Commitment to Social Justice
SOURCE: Gilead Sciences 
Via 3BL Media
Investors Seek Second Act with Moderna Stock
MRNA stock struck gold with its Covid-19 vaccine but investors want to know if there are any other blockbusters in its pipeline. 
Via InvestorPlace
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
From Gilead Sciences, Inc.
Via Business Wire
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
Via Benzinga
Ten Healthcare Companies With High Payout Ratio
The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low. 
Via Talk Markets
Channeling Her Passion to Spread Awareness About TNBC: LaToya's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
10 Biggest Price Target Changes For Monday
Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading. 
Via Benzinga
Opinion: Searching for the Next Generation of Sustainable Health Care
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
What Cramer Thinks About Hims & Hers Health, Gilead Sciences And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Healthcare Realty Trust Incorporated (NYSE: HR) as the company’s merger with Healthcare Trust of America, Inc. 
Via Benzinga
Buy These 3 High-Yield Stocks If You're In Your 50s And Cruise Into Retirement
In your 50s and looking for age-appropriate investments? Fancy yourself some hefty income in lieu of big growth as you age? Want to glide into retirement and land on a sheet of big, safe, totally... 
Via Talk Markets
An Open Letter on Ukraine From Daniel O'Day, Chairman & CEO
SOURCE: Gilead Sciences 
Via 3BL Media
Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Opinion: Why Corporate Philanthropy Must Stand Against Stigma
SOURCE: Gilead Sciences 
Via 3BL Media
Moderna Rockets As It Attempts The Impossible: Vaccinating Against HIV
It hasn't been possible to vaccinate against HIV. Does Moderna stand a chance? 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.58% on an annualized basis. Buying $100 In GILD: 20 years ago, an investor could have... 
Via Benzinga
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,... 
Via Get News
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
44 45 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.